Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
All content for Beginner's Mind is the property of Christian Soschner and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
EP 168 - Alasdair Milton: The Innovation Inflection Point: Why 70% of Cures Never Reach Patients
Beginner's Mind
2 hours 41 minutes
2 weeks ago
EP 168 - Alasdair Milton: The Innovation Inflection Point: Why 70% of Cures Never Reach Patients
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
Beginner's Mind
Breakthrough science has never been stronger — yet patients still miss life-saving therapies. Despite decades of innovation, most precision medicines fail at the last mile of healthcare delivery. The problem isn’t discovery. It’s how science, capital, and systems are aligned — or not. Possessing elite science is no longer enough to win in the multi-trillion-dollar biopharma ecosystem. As innovation shifts from West to East and from treatment to prevention, leadership teams struggle to bridge ...
